DILIsym Partners with Pharma Firm to Begin Model Research for Heart Failure

DILIsym Services, a Simulations Plus company (NASDAQ:SLP), announced that it is developing a new component for a QSP model focused on treating heart failure.

As quoted in the press release:

As with other QSP efforts by the company, the development of this new QSP software component is being sponsored by a large pharmaceutical company partner and will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.

This new venture represents the company’s first project focused on QSP for heart failure. DSS expects the resulting IP to enable a pipeline of heart failure-related consulting and licensing revenue in the future, expanding the company’s addressable market. More importantly, the project illustrates the willingness of DSS to partner with its clients to provide custom solutions to their modeling and simulation needs in the areas of both efficacy and safety.

Click here to read the full press release.